BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marback, E F.
Right arrow Articles by Erwenne, C M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marback, E F.
Right arrow Articles by Erwenne, C M
Topic Collections
Right arrowRelevant Article
British Journal of Ophthalmology 2003;87:1224-1228
© 2003 BMJ Publishing Group Ltd


SCIENTIFIC REPORT

Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma

E Ferrari Marback1, V E A Arias2, A Paranhos, Jr1, F A Soares2, A L Murphree3, C M Erwenne1

1 Federal University of São Paulo, Brazil
2 Hospital do Cancer AC Camargo, São Paulo, Brazil
3 Children’s Hospital Los Angeles, CA, USA

Correspondence to:
Correspondence to:
Associate professor Eduardo Ferrari Marback, Federal University of Bahia, Av Garibaldi 1987/3° andar Salvador, BA 40210-070, Brazil;
eduardomarback{at}hotmail.com


ABSTRACT
Aim: To evaluate tumour angiogenesis as a predictor of prognosis in retinoblastoma.

Methods: This was a retrospective, non-randomised comparative clinicopathological study. The histopathology from 24 cases of Reese-Ellsworth (RE) group V unilateral retinoblastoma treated by enucleation alone was reviewed. Group I consisted of five patients (four RE group Vb and one group Va) who developed disseminated disease at a mean of 10.4 months after enucleation. The remaining 19 patients constitute group II (18 RE group Vb and 1 group Va), none of whom had developed metastatic disease with a mean follow up of 54 months. None of the 24 patients had evidence of extraocular disease at enucleation. The surgical specimens from patients with unilateral retinoblastoma treated by enucleation at Hospital do Cancer AC Camargo between January 1992 and December 1995 were identified, reviewed and the clinical data recorded. Two subsequent histological sections were prepared. One stained with haematoxylin and eosin for assessment of choroidal and optic nerve invasion, and the other for immunoreaction with an endothelium specific marker (antibody anti-CD 34). The main outcome measures were choroidal and/or optic nerve invasion and quantification of the tumour’s relative vascular area (TRVA) obtained by Chalkley counting.

Results: Choroidal invasion was present in three eyes of group I (all massive) and six eyes of group II (two focal and four massive). Optic nerve invasion was found in two eyes of group I (all post-laminar) and four eyes of group II (three prelaminar and one post-laminar). There was no statistical difference regarding choroidal or optic nerve between the two groups. The TRVA was the only independent variable found to predict disease dissemination (p = 0.008 by Cox analysis). A TRVA equal to or greater than 3.9% had 100% sensitivity and 79% specificity in predicting disease dissemination.

Conclusions: Quantification of angiogenesis, through measurement of the TRVA, can help to identify patients with retinoblastoma at high risk for disease dissemination after enucleation.


Keywords: angiogenesis; retinoblastoma


Relevant Article

BJO at a glance
Creig Hoyt
Br. J. Ophthalmol. 2003 87: 1199. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
IOVSHome page
C. M. Cebulla, M.-E. Jockovich, Y. Pina, H. Boutrid, A. Alegret, A. Kulak, A. S. Hackam, S. K. Bhattacharya, W. J. Feuer, and T. G. Murray
Basic Fibroblast Growth Factor Impact on Retinoblastoma Progression and Survival
Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5215 - 5221.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
I A Ajaiyeoba, O O Komolafe, B A Olusanya, and E E U Akang
Histological determinant of mortality in retinoblastoma in Ibadan
Br. J. Ophthalmol., September 1, 2008; 92(9): 1297 - 1298.
[Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
R. J Barry, L. R de Moura, J.-C. Marshall, B. F Fernandes, M. E. Orellana, E. Antecka, C. Martins, and M. N Burnier
Expression of C-kit in retinoblastoma: a potential therapeutic target
Br. J. Ophthalmol., November 1, 2007; 91(11): 1532 - 1536.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M.-E. Jockovich, M. L. Bajenaru, Y. Pina, F. Suarez, W. Feuer, M. E. Fini, and T. G. Murray
Retinoblastoma Tumor Vessel Maturation Impacts Efficacy of Vessel Targeting in the LHBETATAG Mouse Model
Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2476 - 2482.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
M.-E. Jockovich, T. G. Murray, E. Escalona-Benz, E. Hernandez, and W. Feuer
Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice.
Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1264 - 1268.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 by the BMJ Publishing Group Ltd.